Avrobio, inc. (AVRO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating expenses:
Research and development

18,274

17,219

13,042

12,267

12,446

12,809

9,232

7,407

5,647

5,411

1,881

General and administrative

8,315

6,214

5,022

4,345

5,254

3,867

3,000

2,140

2,141

959

661

Total operating expenses

26,589

23,433

18,064

16,612

17,700

16,676

12,232

9,547

7,788

6,370

2,542

Loss from operations

-26,589

-23,433

-18,064

-16,612

-17,700

-16,676

-12,232

-9,547

-7,788

-6,370

-2,542

Other income (expense):
Interest income

632

787

925

565

657

688

646

234

158

7

11

Change in fair value of preferred stock warrant liability

-

-

0

-

-

0

0

150

12

6

-

Change in fair value of derivative liability

-

-

0

-

-

0

0

-1,042

-587

-58

-3

Other expense

16

16

6

8

60

33

5

2

13

14

-

Total other income (expense), net

616

771

919

557

597

655

641

-960

-454

-71

8

Net loss

-25,973

-22,662

-17,145

-16,055

-17,103

-16,021

-11,591

-10,507

-8,242

-6,441

-2,534

Comprehensive loss

-25,973

-22,662

-17,145

-16,055

-17,103

-16,021

-11,591

-10,507

-8,242

-6,441

-2,534

Reconciliation of net loss to net loss attributable to common stockholders:
Net loss

-25,973

-22,662

-17,145

-16,055

-17,103

-16,021

-11,591

-10,507

-8,242

-6,441

-2,534

Accretion of issuance costs on redeemable convertible preferred stock

-

-

-

-

-

0

0

0

2,243

-

-

Net loss attributable to common stockholders—basic and diluted

-

-

-17,145

-16,055

-

-16,021

-11,591

-10,507

-10,485

-6,441

-2,534

Net loss per share attributable to common stockholders—basic and diluted (Note 10)

-0.77

-0.70

-0.57

-0.67

-0.72

4.36

-0.49

-2.98

-4.51

-2.85

-1.15

Weighted-average number of common shares used in computing net loss per share attributable to common stockholders—basic and diluted

33,666

31,493

30,296

24,046

23,893

24,140

23,747

3,529

2,324

2,263

2,202